Maze Therapeutics Reports Positive Phase 2 Data for MZE829
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Source: NASDAQ.COM
Maze Therapeutics' stock is down 20.41% in pre-market trading, crossing below the 5-day SMA.
The decline comes despite the company reporting positive Phase 2 data for MZE829, which showed a 35.6% mean reduction in proteinuria among patients with APOL1-mediated kidney disease. The trial's results indicate significant potential for MZE829, and the company plans to advance it into pivotal clinical programs. However, the stock's pre-market drop suggests a sector rotation, as broader market indices like the Nasdaq-100 and S&P 500 are up.
This situation highlights the volatility in biotech stocks, where positive clinical results may not always translate to immediate stock price gains. Investors may need to consider the overall market conditions and sector performance when evaluating Maze Therapeutics' future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAZE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAZE
Wall Street analysts forecast MAZE stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.400
Low
46.00
Averages
52.00
High
60.00
Current: 25.400
Low
46.00
Averages
52.00
High
60.00
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Maze Therapeutics CEO Jason Coloma Sells $847,000 in Shares Amid Stock Fluctuations
- Executive Share Sale: Maze Therapeutics CEO Jason Coloma sold 32,564 shares in May 2026 for approximately $847,000 at an average price of $26.01 per share, with all shares being indirect holdings, indicating confidence in the company's future prospects.
- Stock Price Context: The sale occurred after a 135.3% increase in share price over the past year, and despite a decline from the 52-week high of $53.65 reached in March, Coloma's sale did not raise investor concerns as it was part of a prearranged trading plan.
- Strong Financial Position: Maze Therapeutics ended Q1 2026 with $362.9 million in cash and cash equivalents, providing a financial runway expected to last until 2029, which supports ongoing clinical trial advancements and efforts to secure FDA approval.
- Clinical Trial Progress: The company is advancing precision medicines for complex renal and metabolic disorders, with Phase 2 trials expected later in 2026, showcasing its ongoing innovation capabilities and market potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Sells 32,564 Shares
- Significant Transaction Size: Maze Therapeutics CEO Jason Coloma sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking his largest single sale to date, exceeding the average historical sale size of about 17,251 shares, which reflects confidence in the company's prospects.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, indicating volatility driven by encouraging clinical trial data.
- Ownership Structure Impact: Following the transaction, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate holdings, which suggests confidence in the company's future.
- Compliance with Trading Plan: The sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to avoid accusations of insider trading, demonstrating that the transaction is part of routine portfolio management rather than a negative signal regarding the company's outlook.
See More
Maze Therapeutics CEO Sells Over 30,000 Shares: Implications for Investors
- Significant Transaction Size: Jason Coloma, CEO of Maze Therapeutics, sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking the largest single sale in his history, exceeding the average historical sale size of about 17,251 shares, indicating his responsiveness to market dynamics.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, highlighting the connection between Coloma's sale and stock price fluctuations.
- Ownership Structure Post-Transaction: Following the sale, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate his holdings, reflecting confidence in the company's future prospects.
- Compliance with Trading Plan: Coloma's sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to mitigate legal risks associated with insider trading, suggesting that the sale is part of routine portfolio management rather than a negative outlook on the company’s future.
See More
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge
- Share Reduction Details: HighVista Strategies disclosed the sale of 70,503 shares of Maze Therapeutics in Q1 2026, an estimated trade valued at $3.11 million, indicating a strategic adjustment in its holdings.
- Ownership Proportion Change: Following this sale, HighVista's stake in Maze Therapeutics decreased to 99,850 shares worth $2.98 million, representing only 0.82% of its reported assets under management, reflecting a cautious stance towards the stock.
- Stock Performance: As of May 14, 2026, Maze Therapeutics shares were priced at $26.43, marking a 180% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its potential.
- Clinical Progress and Market Reaction: Despite reporting positive data for MZE829 in clinical trials, Maze's stock plummeted over 30% post-announcement due to investor concerns about competing therapies, highlighting the market's sensitivity to biotech stock fluctuations.
See More
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Jason Coloma Sells $847,000 in Shares Amid Stock Fluctuations
- Executive Share Sale: Maze Therapeutics CEO Jason Coloma sold 32,564 shares in May 2026 for approximately $847,000 at an average price of $26.01 per share, with all shares being indirect holdings, indicating confidence in the company's future prospects.
- Stock Price Context: The sale occurred after a 135.3% increase in share price over the past year, and despite a decline from the 52-week high of $53.65 reached in March, Coloma's sale did not raise investor concerns as it was part of a prearranged trading plan.
- Strong Financial Position: Maze Therapeutics ended Q1 2026 with $362.9 million in cash and cash equivalents, providing a financial runway expected to last until 2029, which supports ongoing clinical trial advancements and efforts to secure FDA approval.
- Clinical Trial Progress: The company is advancing precision medicines for complex renal and metabolic disorders, with Phase 2 trials expected later in 2026, showcasing its ongoing innovation capabilities and market potential in the biopharmaceutical sector.
See More
Maze Therapeutics CEO Sells 32,564 Shares
- Significant Transaction Size: Maze Therapeutics CEO Jason Coloma sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking his largest single sale to date, exceeding the average historical sale size of about 17,251 shares, which reflects confidence in the company's prospects.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, indicating volatility driven by encouraging clinical trial data.
- Ownership Structure Impact: Following the transaction, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate holdings, which suggests confidence in the company's future.
- Compliance with Trading Plan: The sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to avoid accusations of insider trading, demonstrating that the transaction is part of routine portfolio management rather than a negative signal regarding the company's outlook.
See More
Maze Therapeutics CEO Sells Over 30,000 Shares: Implications for Investors
- Significant Transaction Size: Jason Coloma, CEO of Maze Therapeutics, sold 32,564 common shares between May 22 and May 26, 2026, for approximately $847,000, marking the largest single sale in his history, exceeding the average historical sale size of about 17,251 shares, indicating his responsiveness to market dynamics.
- Market Performance Correlation: This sale coincided with a remarkable 164.34% total return for Maze Therapeutics shares over the past year, with the transaction occurring at a price of around $26.01, compared to a market close of $26.35 on the final sale date, highlighting the connection between Coloma's sale and stock price fluctuations.
- Ownership Structure Post-Transaction: Following the sale, Coloma retains 379,510 shares indirectly held through family trusts, indicating substantial remaining equity and a lack of urgency to liquidate his holdings, reflecting confidence in the company's future prospects.
- Compliance with Trading Plan: Coloma's sale was executed under a prearranged Rule 10b5-1 trading plan established in February 2026, designed to mitigate legal risks associated with insider trading, suggesting that the sale is part of routine portfolio management rather than a negative outlook on the company’s future.
See More
HighVista Strategies Sells Shares of Maze Therapeutics Amid Stock Surge
- Share Reduction Details: HighVista Strategies disclosed the sale of 70,503 shares of Maze Therapeutics in Q1 2026, an estimated trade valued at $3.11 million, indicating a strategic adjustment in its holdings.
- Ownership Proportion Change: Following this sale, HighVista's stake in Maze Therapeutics decreased to 99,850 shares worth $2.98 million, representing only 0.82% of its reported assets under management, reflecting a cautious stance towards the stock.
- Stock Performance: As of May 14, 2026, Maze Therapeutics shares were priced at $26.43, marking a 180% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its potential.
- Clinical Progress and Market Reaction: Despite reporting positive data for MZE829 in clinical trials, Maze's stock plummeted over 30% post-announcement due to investor concerns about competing therapies, highlighting the market's sensitivity to biotech stock fluctuations.
See More
Maze Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Maze Therapeutics reported a Q1 GAAP EPS of -$0.45, beating expectations by $0.10, indicating an improvement in financial performance despite ongoing losses.
- License Revenue Surge: The company achieved $20 million in license revenue for Q1, exceeding market expectations by $11.5 million, suggesting increasing market acceptance and demand for its products.
- Stable Cash Reserves: As of March 31, 2026, Maze's cash, cash equivalents, and marketable securities totaled $362.9 million, a slight increase from $360.0 million on December 31, 2025, demonstrating solid financial management.
- Future Funding Outlook: Maze anticipates that its cash reserves, along with proceeds from the registered offering completed in April 2026 and a $20 million milestone payment from Shionogi & Co., Ltd., will fund operations into 2029, reflecting confidence in its future growth plans.
See More
Maze Therapeutics Executive Stock Transaction Overview
- Executive Stock Transaction: Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and immediately sold 7,500 shares of common stock on April 29, 2026, for approximately $190,000, indicating a strategic liquidity management approach by the company's executives.
- Holding Changes: Dandekar's direct stock holdings were reduced by 41.66%, yet he retains 44,143 stock options, suggesting ongoing potential for equity exposure and continued interest in the company's future prospects.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan, reflecting consistency with prior administrative transactions, and while the trade size has decreased, it still demonstrates Dandekar's confidence in the company's trajectory.
- Market Performance: Maze Therapeutics' stock has surged by 192% over the past year, closing at $25.68 on April 29, 2026, highlighting the company's strong growth potential in the biopharmaceutical sector.
See More
